BioSpace News Archive

Ayala Pharmaceuticals, Inc. announced that Ayala management will participate in two upcoming virtual investor conferences in September.

Cidara Therapeutics, Inc., a biotechnology company developing long-acting compounds designed to transform the standard of care for prevention and treatment of serious diseases, announced that it will host a research and development day webinar on Tuesday, September 21, 2021 from 10am to 12pm Eastern Time.

Keros Therapeutics, Inc. announced that Keros’ President and Chief Executive Officer Jasbir S. Seehra, Ph.D., will participate in two upcoming healthcare conferences.

MaxCyte, Inc., (NASDAQ: MXCT; LSE: MXCT, MXCN), a leading provider of enabling platform technologies for ex vivo cell engineering, today announced that it will release financial results for the second quarter of 2021 after the U.S. market close on Monday, September 13th, 2021.

Vor Biopharma, a cell and genome engineering company, announced that the Company will be participating in three upcoming virtual investor conferences.

Celsion Corporation (NASDAQ: CLSN), today announced results from preclinical in vivo studies showing production of antibodies and cytotoxic T-cell response specific to the spike antigen of SARS-CoV-2 when immunizing BALB/c mice with the Company’s next-generation PLACCINE DNA vaccine platform.

Lumos Pharma, Inc., a clinical-stage biopharmaceutical company focused on therapeutics for rare diseases, announced that the Company will participate in the H.C. Wainwright 23rd Annual Global Investment Conference and the Cantor Virtual Global Healthcare Conference in September.

Pliant Therapeutics, Inc., a clinical stage biotechnology company focused on discovering and developing novel therapeutics for the treatment of fibrosis, announced participation in the following investor conferences.

MEI Pharma, Inc., a late-stage pharmaceutical company focused on advancing new therapies for cancer, announced that it will present a company overview and business update at two upcoming investor conferences.

Blueprint Medicines Corporation (NASDAQ: BPMC) today announced that Kate Haviland, Blueprint Medicines’ Chief Operating Officer, and Fouad Namouni, M.D., Blueprint Medicines’ President, Research & Development, will participate virtually in a fireside chat at the Morgan Stanley 19th Annual Global Healthcare Conference.